



Interim Report Released

The Q2 2018 Interim Report covering the period of 1 April 2018 to 30 June 2018 was released on 21 August 2018.

The results we posted this quarter represent a very important milestone for Dignitana. Quarterly revenue for the company reached 9,022 TSEK. With the organizational restructuring we have implemented, the company is close to reaching a breakeven point in regard to our costs for continuing operations. You can download the Q2 2018 Interim Report at www.dignitana.se/rapporter

September 11 Aktiespararna Stockholm Event to feature Dignitana CEO William Cronin

Dignitana Chief Executive Officer William Cronin will speak at Aktiespararna's event [Aktiedagen Stockholm](#) on 11 September 2018. Mr. Cronin's 20-minute presentation will be webcast live starting at 11:20 am CET and published the following day. Event attendees will have the opportunity to ask Mr. Cronin questions following his presentation.

The event is hosted by Aktiespararna, an independent organization working in the interest of private individuals who invest in stocks, mutual funds and other stock-related securities.

The [Aktiedagen Stockholm](#) will be held at Operaterrassen, Karl XII Square, Stockholm. Admission is free, but those who wish to attend must contact event@aktiespararna.se to register. To access Dignitana's presentation live, please visit: aktiespararna.se/tv/live. The presentation will be posted the following day on www.dignitana.se

Investor Relations Communication

1. The email address for investor relations is investorrelations@dignitana.com.

2. Per MAR guidelines, inside information will be posted at www.dignitana.se and distributed to Nasdaq OMX, First North Stockholm, Nordic News Agencies, EU Transparency, and financial websites.

3. IN BRIEF is the monthly newsletter for Dignitana Shareholders. The first week of each month IN BRIEF will be posted at www.dignitana.se/newsletter.

[Click here to subscribe](#) to receive this newsletter by email each month

DigniCap in the U.S.

The DigniCap Scalp Cooling System is now [available](#) at 106 locations in the U.S. representing 144 machines. The past month has provided several contract renewals and additional machines installed at two facilities.

Shareholder Questions

When will you apply again to the American Medical Association for the coding that will assist U.S. patients with insurance reimbursement?

We learned a tremendous amount during the process of applying for a CPT code last spring. The key finding was that the AMA is looking for widespread usage before issuing a unique code, and we know that the usage they are looking for will take time to establish. Patients in the U.S. can apply for insurance reimbursement now – it just requires paperwork on their part and the coverage is not consistent.

The new system is expected to be introduced to the market in late 2018 or early 2019 according to the report. Does this include time for FDA clearance?

We plan to have the new machine ready to submit to the FDA by the end of 2018.

Neuropathy and oral mucositis are two side effects of chemotherapy which can be reduced by cooling the feet, hands and mouth. Would Dignitana consider potentially offering treatment for all three of these side effects in the future?

We are aware of the interest in providing cooling to address the two other side effects and know that pursuing that treatment would require considerable resources for clinical trials. At the current time we are focused on scalp cooling to minimize hair loss and on optimizing the outcomes of that treatment.

When will Dignitana reach breakeven and will there be a need for an additional loan or other solution for more money?

We continue to work toward reaching breakeven in costs for continuing operations as quickly as possible. We set the goal to attain that level in Q4 and came very close to reaching it in Q2.

What is happening DigniCap in Asia?

We are currently working with Konica Minolta to establish the necessary regulatory pathways for sales in Asia. Discussions are ongoing and positive.